Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
News|Videos|June 1, 2025
ERA 2025 Preview: Late Breakers to Watch, with Brendon Neuen, MBBS, PhD
Author(s)Brendon Neuen, MD
Fact checked by: Patrick Campbell
Brendon Neuen, MBBS, PhD, discusses 3 late breaking clinical trials being presented at ERA 2025.
Advertisement
Advertisement
From June 4–7, the nephrology world converges in Vienna for the
Related to this article
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
Advertisement
Advertisement